enGene Presents Promising EG-70 Data for Bladder Cancer Treatment at AUA 2024

enGene Holdings presents promising data for EG-70, a novel bladder cancer treatment, at the American Urology Association 2024 Annual Meeting. The treatment shows complete response rates of 70% and 60% at three and six months, respectively, in high-risk patients.

author-image
Quadri Adejumo
New Update
enGene Presents Promising EG-70 Data for Bladder Cancer Treatment at AUA 2024

enGene Presents Promising EG-70 Data for Bladder Cancer Treatment at AUA 2024

enGene Holdings Inc. (NASDAQ:ENGN) announced the present, details of promising data for its investigational bladder cancer treatment EG-70 at the American Urology Association (AUA) 2024 Annual Meeting, held from May 3-6, 2024, in San Antonio, Texas. The oral presentation, titled "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)," was given by Dr. Gordon Brown.

Why this matters: The development of effective treatments for bladder cancer is vital, with high recurrence rates and limited treatment options posing a significant public health burden. The success of EG-70 could lead to improved patient outcomes and quality of life, and reduced healthcare costs associated with managing this disease. The development of effective treatments for bladder cancer is vital, with high recurrence rates and limited treatment options posing a significant public health burden. The success of EG-70 could lead to improved patient outcomes and quality of life, resulting in reduced healthcare costs associated with managing this disease.

EG-70 is a non-viral, non-infectious, locally delivered genetic medicine designed to address challenges in intravesical treatment options for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The presentation highlighted the rational design of EG-70, which considers preparation, handling, and safety considerations. Dr. Brown presented the complete dataset from the 12-month follow-up of all patients in the Phase 1 portion of the LEGEND study.

The data showed that EG-70 demonstrated promising initial efficacy and safety in high-risk, BCG-unresponsive NMIBC patients with CIS. The treatment showed complete response rates of 70% and 60% at three months and six months, respectively, in the subgroup of patients who received the optimized Phase 2 dose. Notably, the safety data suggest that this efficacy was achieved without significant impairment to the patients' quality of life.

Dr. Dr. Gordon Brown expressed his satisfaction with presenting the comprehensive overview of EG-70 and the LEGEND study, stating, "I am pleased to present a thorough overview of EG-70 and the landmark Phase 1/2 LEGEND study. EG-70 is designed to be a practice-changing product that does not require a change in practice for urologists, offering attributes that render it practical for use in community-based and high-volume clinics."

Dr. Dr. Richard Bryce, enGene's Chief Medical Officer, highlighted the potential of EG-70 to make genetic medicine accessible to all urologists, saying, "The promising initial efficacy and safety data from LEGEND's Phase 1 cohort in high-risk, BCG-unresponsive NMIBC patients with CIS, combined with its ease of handling, simplicity of administration, minimal storage requirements, and lack of post-procedural patient restrictions, demonstrate EG-70's potential to harness the power of genetic medicine for any and all urologists."

Jason Hanson, Chief Executive Officer of enGene, emphasized the rational design of EG-70, stating, "EG-70 was rationally designed to be easy to use and meet the needs of patients and urologists alike. As a non-viral, non-infectious, locally delivered genetic medicine, EG-70 is designed to synergistically activate both the innate and adaptive immune responses, be easily reconstituted in water, and require only a short procedural time."

The presentation of EG-70 data at the prestigious AUA Annual Meeting highlights the potential significance of this innovative treatment approach for patients with BCG-unresponsive NMIBC. As enGene continues to advance the development of EG-70, the medical community and patients eagerly await further results from ongoing clinical trials. The promising initial data provide hope for improved outcomes and quality of life for individuals facing the challenges of this difficult-to-treat cancer.

Key Takeaways

  • enGene presents promising data for EG-70, a novel bladder cancer treatment, at AUA 2024.
  • EG-70 shows 70% and 60% complete response rates at 3 and 6 months, respectively, in Phase 1 study.
  • Treatment demonstrates safety and efficacy in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients.
  • EG-70 is a non-viral, non-infectious, locally delivered genetic medicine designed for ease of use and minimal storage requirements.
  • Success of EG-70 could lead to improved patient outcomes, quality of life, and reduced healthcare costs.